Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00322595
Status:
COMPLETED
Last Update Posted:
2008-12-22
First Post:
2006-05-05
Brief Title:
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An International Multicenter Randomized Double-Blind Parallel-Group Placebo-Controlled Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate Seroquel SR in the Treatment of Generalized Anxiety Disorder SILVER
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SILVER
Brief Summary:
The primary purpose of this study is to evaluate the efficacy of SEROQUEL SR quetiapine fumarate sustained-release SR compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder GAD
PLEASE NOTE Seroquel SR and Seroquel XR refer to the same formulation The SR designation was changed to XR after consultation with FDA
PLEASE NOTE Seroquel SR and Seroquel XR refer to the same formulation The SR designation was changed to XR after consultation with FDA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Silver | None | None | None |
| 2005-005054-46 | None | None | None |